This study involves people with Chronic Obstructive Pulmonary Disease, also known as COPD, which is a long-term lung condition that makes breathing difficult and causes symptoms like coughing and mucus production. The study is looking at a medication called Tozorakimab, which is also known by its code name MEDI3506. Some participants will receive Tozorakimab while others will receive placebo. Participants may also use Salbutamol, which is a type of short-acting medication that helps open the airways when breathing becomes difficult. All participants will continue using their regular COPD medications during the study.
The purpose of this study is to see whether Tozorakimab can reduce the number of times COPD symptoms suddenly get worse, which are called exacerbations. These exacerbations are episodes when breathing problems become more severe than usual and may require additional treatment or even hospitalization. The study will compare two different amounts of Tozorakimab given as an injection under the skin to placebo, which will be added to the standard medications that participants are already taking for their COPD.
The study will last for about 52 weeks. During this time, participants will receive regular injections of either Tozorakimab or placebo, and doctors will monitor how often their COPD symptoms worsen and how severe these episodes are. The study focuses on people who have had at least two moderate episodes or one severe episode of worsening COPD symptoms in the past year, who are former smokers, and who continue to have symptoms despite using their regular COPD medications.
Belgium 
Bulgaria 
Czechia 
Denmark 
Finland 
Hungary 
Norway 
Portugal 
Spain 
Sweden 
The Netherlands 
